126 related articles for article (PubMed ID: 26864076)
1. Alpha-synuclein: relating metals to structure, function and inhibition.
McDowall JS; Brown DR
Metallomics; 2016 Apr; 8(4):385-97. PubMed ID: 26864076
[TBL] [Abstract][Full Text] [Related]
2. The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson's disease.
Sian-Hulsmann J; Riederer P
J Neural Transm (Vienna); 2020 May; 127(5):749-754. PubMed ID: 32318880
[TBL] [Abstract][Full Text] [Related]
3. Interactions between metals and alpha-synuclein--function or artefact?
Brown DR
FEBS J; 2007 Aug; 274(15):3766-74. PubMed ID: 17617226
[TBL] [Abstract][Full Text] [Related]
4. Iron and other metals in the pathogenesis of Parkinson's disease: Toxic effects and possible detoxification.
Bjørklund G; Hofer T; Nurchi VM; Aaseth J
J Inorg Biochem; 2019 Oct; 199():110717. PubMed ID: 31369907
[TBL] [Abstract][Full Text] [Related]
5. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the metal status of natively purified alpha-synuclein from human blood, brain tissue, or recombinant sources using size exclusion ICP-MS reveals no significant binding of Cu, Fe or Zn.
Lothian A; Lago L; Mukherjee S; Connor AR; Fowler C; McLean CA; Horne M; Masters CL; Cappai R; Roberts BR
Metallomics; 2019 Jan; 11(1):128-140. PubMed ID: 30465671
[TBL] [Abstract][Full Text] [Related]
7. Effects of alpha-synuclein post-translational modifications on metal binding.
González N; Arcos-López T; König A; Quintanar L; Menacho Márquez M; Outeiro TF; Fernández CO
J Neurochem; 2019 Sep; 150(5):507-521. PubMed ID: 31099098
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
9. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
Zhang W; Wang T; Pei Z; Miller DS; Wu X; Block ML; Wilson B; Zhang W; Zhou Y; Hong JS; Zhang J
FASEB J; 2005 Apr; 19(6):533-42. PubMed ID: 15791003
[TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein and its role in metal binding: relevance to Parkinson's disease.
Wright JA; Brown DR
J Neurosci Res; 2008 Feb; 86(3):496-503. PubMed ID: 17705291
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
[TBL] [Abstract][Full Text] [Related]
12. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
13. Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease.
Bharathi ; Rao KS
Biochem Biophys Res Commun; 2007 Jul; 359(1):115-20. PubMed ID: 17531952
[TBL] [Abstract][Full Text] [Related]
14. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
Liu IH; Uversky VN; Munishkina LA; Fink AL; Halfter W; Cole GJ
Glycobiology; 2005 Dec; 15(12):1320-31. PubMed ID: 16037493
[TBL] [Abstract][Full Text] [Related]
15. Dopamine complexes of iron in the etiology and pathogenesis of Parkinson's disease.
Arreguin S; Nelson P; Padway S; Shirazi M; Pierpont C
J Inorg Biochem; 2009 Jan; 103(1):87-93. PubMed ID: 18976814
[TBL] [Abstract][Full Text] [Related]
16. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells.
Yamakawa K; Izumi Y; Takeuchi H; Yamamoto N; Kume T; Akaike A; Takahashi R; Shimohama S; Sawada H
Biochem Biophys Res Commun; 2010 Jan; 391(1):129-34. PubMed ID: 19900407
[TBL] [Abstract][Full Text] [Related]
17. The Interaction of Alpha-synuclein with Membranes and its Implication in Parkinson's Disease: A Literature Review.
Gonzalez-Horta A
Nat Prod Commun; 2015 Oct; 10(10):1775-8. PubMed ID: 26669123
[TBL] [Abstract][Full Text] [Related]
18. Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice.
Finkelstein DI; Hare DJ; Billings JL; Sedjahtera A; Nurjono M; Arthofer E; George S; Culvenor JG; Bush AI; Adlard PA
ACS Chem Neurosci; 2016 Jan; 7(1):119-29. PubMed ID: 26481462
[TBL] [Abstract][Full Text] [Related]
19. Α-synuclein misfolding and Parkinson's disease.
Breydo L; Wu JW; Uversky VN
Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
[TBL] [Abstract][Full Text] [Related]
20. Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein.
Sarafian TA; Yacoub A; Kunz A; Aranki B; Serobyan G; Cohn W; Whitelegge JP; Watson JB
J Neurosci Res; 2019 Dec; 97(12):1689-1705. PubMed ID: 31420910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
